Protocol of the study: the effectiveness of pleuran in the treatment of acute gastroenteritis in children-a randomised, placebo-controlled, double-blind trial (EPTAGE)

Katarzyna Wzorek-Łyczko, Anna Piwowarczyk, Ernest Kuchar, Katarzyna Wzorek-Łyczko, Anna Piwowarczyk, Ernest Kuchar

Abstract

Introduction: Acute gastroenteritis is one of the most common causes of children's morbidity and mortality globally. Oral or intravenous rehydration was proven effective in reducing the mortality rates in acute gastroenteritis, although it does not affect the course of the disease. Attempts to identify new therapeutic methods effective in reducing the symptoms of diarrhoea are of interest. Pleuran's potential immunomodulatory effect in acute gastrointestinal infection relies on the stimulation of innate immunity. The effectiveness of pleuran (β-(1,3/1,6)-d-glucan) administration to treat acute infectious diarrhoea remains unknown. This study evaluates the efficacy of pleuran in reducing diarrhoea duration and the severity of acute gastroenteritis symptoms in children.

Methods and analysis: Our study is a randomised, double-blind, placebo-controlled superiority trial with two parallel groups and a 1:1 allocation ratio. A total of 120 children aged 2-10 years hospitalised or requiring a visit to the emergency department because of acute gastroenteritis will be randomly assigned to receive either pleuran oral suspension in the experimental group or matching placebo in the control group. The primary outcome measure will be the duration of diarrhoea. We will analyse the results in both intention-to-treat and per-protocol approaches.

Ethics and dissemination: The Bioethics Committee of The Medical University of Warsaw approved the study protocol (approval number: KB/45/2018). Written informed consent of the patients' caregivers participating in the study will be obligatory. The results of this study will be published in a medical journal, regardless of whether they confirm or deny the research hypothesis.

Trial registration number: NCT03988257; Pre-results.

Keywords: gastrointestinal infections; paediatric gastroenterology; paediatric infectious disease & immunisation.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Fitzwater S, Chandran A, Kosek M. Infectious diarrhea. : Selendy JMH, . Water and sanitation-related diseases and the environment: challenges, interventions, and preventive measures. John Wiley and Sons, 2011: 47–70.
    1. World Health Organization . The global burden of disease: 2004 update, 2008. Available: [Accessed Jun 2020].
    1. Pediatric ROTavirus European CommitTee (PROTECT) . The paediatric burden of rotavirus disease in Europe. Epidemiol Infect 2006;134:908–16. 10.1017/S0950268806006091
    1. Guarino A, Ashkenazi S, Gendrel D. ESPGHAN/ESPID Evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr 2014;59:132–52.
    1. Freedman SB, Ali S, Oleszczuk M, et al. . Treatment of acute gastroenteritis in children: an overview of systematic reviews of interventions commonly used in developed countries. Evid Based Child Health 2013;8:1123–37. 10.1002/ebch.1932
    1. NICE . Diarrhoea and vomiting caused by gastroenteritis in under 5S: diagnosis and management. NICE clinical guidelines. Available: [Accessed Jun 2020].
    1. Hojsak I, Fabiano V, Pop TL. European guidance on paediatric use of probiotics states that benefits are limited to several conditions and urges caution with specific vulnerable groups. Acta Paediatr 2018;107:927–37.
    1. Szajewska H, Guarino A, Hojsak I, et al. . Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working group for probiotics and prebiotics. J Pediatr Gastroenterol Nutr 2014;58:531–9. 10.1097/MPG.0000000000000320
    1. van den Berg J, Berger MY. Guidelines on acute gastroenteritis in children: a critical appraisal of their quality and applicability in primary care. BMC Fam Pract 2011;12:134. 10.1186/1471-2296-12-134
    1. Pérez-Gaxiola G, Cuello-García CA, Florez ID, et al. . Smectite for acute infectious diarrhoea in children. Cochrane Database Syst Rev 2018;4:CD011526. 10.1002/14651858.CD011526.pub2
    1. Liang Y, Zhang L, Zeng L, et al. . Racecadotril for acute diarrhoea in children. Cochrane Database Syst Rev 2019;12:CD009359. 10.1002/14651858.CD009359.pub2
    1. Lazzerini M, Ronfani L. Oral zinc for treating diarrhoea in children. Cochrane Database Syst Rev 2012;6:CD005436.
    1. Florez ID, Veroniki A-A, Al Khalifah R, et al. . Comparative effectiveness and safety of interventions for acute diarrhea and gastroenteritis in children: a systematic review and network meta-analysis. PLoS One 2018;13:e0207701. 10.1371/journal.pone.0207701
    1. MacGillivray S, Fahey T, McGuire W. Lactose avoidance for young children with acute diarrhoea. Cochrane Database Syst Rev 2013;10:CD005433. 10.1002/14651858.CD005433.pub2
    1. Di Luzio NR. Update on the immunomodulating activities of glucans. Springer Semin Immunopathol 1985;8:387–400. 10.1007/BF01857392
    1. Chan GC-F, Chan WK, Sze DM-Y. The effects of β-glucan on human immune and cancer cells. J Hematol Oncol 2009;2:25. 10.1186/1756-8722-2-25
    1. Tsukada C, Yokoyama H, Miyaji C, et al. . Immunopotentiation of intraepithelial lymphocytes in the intestine by oral administrations of beta-glucan. Cell Immunol 2003;221:1–5. 10.1016/S0008-8749(03)00061-3
    1. Jesenak M, Majtan J, Rennerova Z, et al. . Immunomodulatory effect of pleuran (β-glucan from Pleurotus ostreatus) in children with recurrent respiratory tract infections. Int Immunopharmacol 2013;15:395–9. 10.1016/j.intimp.2012.11.020
    1. Jesenak M, Sanisló E, Kuniakova R. Imunoglukan P4H® in the prevention of recurrent respiratory infections in childhood. Cesk Pediatr 2010;65:639–47.
    1. Pasnik J, Ślemp A, Cywinska-Bernas A. Preventive effect of pleuran (β-glucan from Pleurotus ostreatus) in children with recurrent respiratory tract infections – an open-label prospective study. Curr Pediatr Res 2017;21:99–104.
    1. Grau JS, Sirvent LP, Ingles MM. Beta-glucans from Pleurotus ostreatus for prevention of recurrent respiratory tract infections. Acta Pediatrica Espanola 2015;73:186–93.
    1. Urbancikova I, Hudackova D, Majtan J, et al. . Efficacy of Pleuran (β-Glucan from Pleurotus ostreatus) in the Management of Herpes Simplex Virus Type 1 Infection. Evid Based Complement Alternat Med 2020;2020:1–8. 10.1155/2020/8562309
    1. Jesenak M, Urbancek S, Majtan J, et al. . β-Glucan-based cream (containing pleuran isolated from Pleurotus ostreatus) in supportive treatment of mild-to-moderate atopic dermatitis. J Dermatolog Treat 2016;27:351–4. 10.3109/09546634.2015.1117565
    1. Bergendiova K, Tibenska E, Majtan J. Pleuran (β-glucan from Pleurotus ostreatus) supplementation, cellular immune response and respiratory tract infections in athletes. Eur J Appl Physiol 2011;111:2033–40. 10.1007/s00421-011-1837-z
    1. Bobovcák M, Kuniaková R, Gabriž J, et al. . Effect of Pleuran (β-glucan from Pleurotus ostreatus) supplementation on cellular immune response after intensive exercise in elite athletes. Appl Physiol Nutr Metab 2010;35:755–62. 10.1139/H10-070
    1. Wojtyniak K, Szajewska H, Dziechciarz P. Translation to Polish, cross-cultural adaptation, and validation of the Bristol stool form scale among healthcare professionals and patients. Prz Gastroenterol 2018;13:35–9. 10.5114/pg.2017.70610
    1. World Health Organization . The child growth standards: BMI-for-age. Available:
    1. Schnadower D, Tarr PI, Gorelick MH, et al. . Validation of the modified Vesikari score in children with gastroenteritis in 5 US emergency departments. J Pediatr Gastroenterol Nutr 2013;57:514–9. 10.1097/MPG.0b013e31829ae5a3
    1. World Health Organization . Cholera. fact sheet 107, 2012. Available: [Accessed Jun 2020].
    1. Friedman JN, Goldman RD, Srivastava R, et al. . Development of a clinical dehydration scale for use in children between 1 and 36 months of age. J Pediatr 2004;145:201–7. 10.1016/j.jpeds.2004.05.035
    1. Altman DG. Statistics and ethics in medical research: III how large a sample? Br Med J 1980;281:1336–8. 10.1136/bmj.281.6251.1336
    1. Chan A-W, Tetzlaff JM, Altman DG, et al. . SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200–7. 10.7326/0003-4819-158-3-201302050-00583

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться